DPP4 and metabolic syndrome: DPP-4 inhibitors significantly lowered the risk of eGFR decline > 10% [hazard ratio (HR), 0.830; 95% CI, 0.715–0.964; P = 0.015], as well as the occurrence of dyslipidemia (HR, 0.834; 95% CI, 0.698–0.996; P = 0.045).